BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	86.13	112.45	306.24	507.73	274.35	115.72
Short-Term Investments	252.22	278.34	119.54	3.21	28.24	22.05
Cash & Cash Equivalents	338.35	390.79	425.78	510.95	302.59	137.78
Cash Growth	-15.33%	-8.22%	-16.67%	68.86%	119.62%	29.96%
Receivables	60.59	56.95	50.6	29.41	8.65	22.15
Inventory	29.78	28.68	27.53	15.79	7.04	0
Other Current Assets	18.38	19.54	12.59	9.99	5.53	4.42
Total Current Assets	447.1	495.97	516.5	566.14	323.8	164.35
Property, Plant & Equipment	7.83	7.91	8.62	8.71	7.11	7.35
Long-Term Investments	0	0	18.08	6.83	0	0
Other Long-Term Assets	12.96	13.08	6.81	6.47	3.8	3.59
Total Long-Term Assets	20.79	20.99	33.5	22.02	10.92	10.94
Total Assets	467.89	516.96	550	588.15	334.72	175.28
Accounts Payable	11.91	20.89	14.36	27.81	18.71	13.99
Deferred Revenue	0	0	1.22	1.42	0.15	2.12
Current Debt	28.76	26.21	2.37	1.82	31.18	39.96
Other Current Liabilities	79.25	102.88	87.57	72.67	55.61	36.27
Total Current Liabilities	119.92	149.99	105.51	103.72	105.65	92.34
Long-Term Debt	824.14	822.5	739.08	591.42	248.32	44.7
Total Long-Term Liabilities	824.14	822.5	739.08	591.42	248.32	44.7
Total Liabilities	944.06	972.49	844.6	695.14	353.98	137.03
Total Debt	852.9	848.71	741.45	593.24	279.5	84.65
Debt Growth	12.91%	14.47%	24.98%	112.25%	230.17%	36.93%
Retained Earnings	-1,716.54	-1,681.16	-1,454.62	-1,207.5	-1,023.44	-840.63
Comprehensive Income	0.77	1.34	0.03	0.18	0	0.04
Shareholders' Equity	-476.17	-455.53	-294.6	-106.99	-19.26	38.25
Net Cash / Debt	-514.55	-457.92	-315.67	-82.29	23.09	53.12
Net Cash / Debt Growth	-	-	-	-	-56.55%	20.22%
Net Cash Per Share	-2.50	-2.38	-1.70	-0.46	0.14	0.46
Working Capital	327.18	345.98	410.99	462.42	218.15	72.01
Book Value Per Share	-2.31	-2.37	-1.58	-0.60	-0.12	0.33

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).